Docket No.: V0139.70071US00




Fig. 1A




Fig. 1B




Fig. 2




Fig. 3




Fig. 4





Fig. 5






Fig. 6






Fig. 7

Docket No.: V0139.70071US00





Fig. 8



(C)	LANE	TREATMENT	NORMALIZED AREA	APOPTOTIC INDEX
	1	MEDIUM ALONE	0.0711	0.0000
	2	17/227	0.4168	0.3722
	3	14-4-45	0.2309	0.1721
	4	10-2.16	0.6850	0.6609
	5	H116-32	0.7183	0.6968
	6	ISOPROTERENOL	1.0000	1.0000
	7	dbcAMP	1.0304	1.0328

Fig. 9

Docket No.: V0139.70071US00




Fig. 10




Fig. 11

Docket No.: V0139.70071US00




Fig. 12

Docket No.: V0139.70071US00

14/24




Fig. 13A







Fig. 13B

Docket No.: V0139.70071US00



Docket No.: V0139.70071US00





DATA #1






Fig. 17A





Docket No.: V0139.70071US00






Fig. 19

Methods and Products Related to Metabolic Interactions in Disease

Martha K. Newell

Docket No.: V0139.70071US00

20/24



CD4+CD3 CD28 CD3 CD4 NO TREATMENT

Fig. 20




Fig. 21

Docket No.: V0139.70071US00




Fig. 22




Fig. 23




Fig. 24




Fig. 25